Publication:
Cancer-Free Survival of Psoriasis Patients Treated with Methotrexate and Cyclosporine Combination

dc.authorscopusid7004347982
dc.authorscopusid14326498900
dc.authorscopusid6603682965
dc.authorscopusid6601978714
dc.authorscopusid6603561910
dc.contributor.authorAydin, F.
dc.contributor.authorYüksel, E.P.
dc.contributor.authorŞentürk, N.
dc.contributor.authorCantürk, T.
dc.contributor.authorTuranli, A.Y.
dc.date.accessioned2020-06-21T13:56:48Z
dc.date.available2020-06-21T13:56:48Z
dc.date.issued2014
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Aydin] Fatma, Department of Dermatology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Yüksel] Esra Pancar, Department of Dermatology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Şentürk] Nilgün, Department of Dermatology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Cantürk] Tayyar, Department of Dermatology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Turanli] Ahmet Yaşar, Department of Dermatology, Ondokuz Mayis Üniversitesi, Samsun, Turkeyen_US
dc.description.abstractContext: Combination of methotrexate and cyclosporine was used and reported to be effective for recalcitrant psoriasis patients. Also each agent is accused for development of malignancies. Objective: To evaluate the cancer-free survival of psoriasis patients who received methotrexate and cyclosporine treatment at the same time. Methods: Psoriasis patients who had been treated with combination of cyclosporine and methotrexate between March 2000 and April 2005 were questioned in 2011. A diagnosis of new cancer during follow-up period was asked and also each patient was evaluated by a questionnaire. Results: Seventeen psoriasis patients were not treated due to a diagnosis of new cancer during the follow-up period. Also none of them complained of possible symptoms of skin or lymphoproliferative malignancies. The median follow-up time was 76 months. Conclusion: Psoriasis patients who had been treated with methotrexate and cyclosporine combination did not report a detected malignant disease. © 2014 Informa Healthcare USA, Inc. All rights reserved: reproduction in whole or part not permitted.en_US
dc.identifier.doi10.3109/15569527.2013.825805
dc.identifier.endpage183en_US
dc.identifier.issn1556-9527
dc.identifier.issn1556-9535
dc.identifier.issue3en_US
dc.identifier.pmid23944659
dc.identifier.scopus2-s2.0-84906669926
dc.identifier.scopusqualityQ3
dc.identifier.startpage181en_US
dc.identifier.urihttps://doi.org/10.3109/15569527.2013.825805
dc.identifier.volume33en_US
dc.identifier.wosWOS:000341288800002
dc.identifier.wosqualityQ3
dc.language.isoenen_US
dc.publisherInforma Healthcare healthcare.enquiries@informa.comen_US
dc.relation.ispartofCutaneous and Ocular Toxicologyen_US
dc.relation.journalCutaneous and Ocular Toxicologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCyclosporineen_US
dc.subjectMalignancyen_US
dc.subjectMethotrexateen_US
dc.subjectPsoriasisen_US
dc.titleCancer-Free Survival of Psoriasis Patients Treated with Methotrexate and Cyclosporine Combinationen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files